Brokerages Set OrthoPediatrics Corp. (NASDAQ:KIDS) Target Price at $34.14

OrthoPediatrics Corp. (NASDAQ:KIDS) has been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $34.1429.

Several brokerages recently weighed in on KIDS. JMP Securities set a $35.00 target price on shares of OrthoPediatrics and gave the company a “market outperform” rating in a report on Friday, August 8th. Citigroup restated a “market outperform” rating on shares of OrthoPediatrics in a report on Friday, August 8th. BTIG Research lowered their target price on shares of OrthoPediatrics from $40.00 to $39.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Wall Street Zen raised OrthoPediatrics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Finally, Piper Sandler decreased their price target on OrthoPediatrics from $40.00 to $30.00 and set an “overweight” rating for the company in a report on Thursday, May 8th.

OrthoPediatrics Trading Up 1.8%

KIDS opened at $19.48 on Friday. The business has a fifty day moving average price of $21.11 and a 200 day moving average price of $22.30. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.66 and a quick ratio of 3.43. OrthoPediatrics has a 12 month low of $16.59 and a 12 month high of $33.14. The stock has a market capitalization of $488.36 million, a price-to-earnings ratio of -10.88 and a beta of 1.12.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.06. The company had revenue of $61.08 million for the quarter, compared to analyst estimates of $61.40 million. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%. OrthoPediatrics has set its FY 2025 guidance at EPS. Sell-side analysts expect that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OrthoPediatrics

Several hedge funds have recently added to or reduced their stakes in KIDS. Los Angeles Capital Management LLC acquired a new stake in OrthoPediatrics during the second quarter worth approximately $220,000. Wells Fargo & Company MN raised its stake in OrthoPediatrics by 31.1% during the 4th quarter. Wells Fargo & Company MN now owns 9,853 shares of the company’s stock worth $228,000 after acquiring an additional 2,338 shares in the last quarter. PDT Partners LLC purchased a new stake in OrthoPediatrics in the first quarter valued at $244,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after acquiring an additional 645 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in OrthoPediatrics by 4,618.2% in the first quarter. GAMMA Investing LLC now owns 10,616 shares of the company’s stock valued at $261,000 after acquiring an additional 10,391 shares in the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.